Calendar

Cloudflare has strong underlying revenue growth and a Q3 company revenue guide of $736–737M, but the pre-event tape deteriorated sharply: the stock fell 9.5% on October 30 and was reported down about 20% over 20 sessions. The checked close location on October 30 was approximately 0.32; no positive quarter-specific EPS revision, qualifying close, or abnormal-volume accumulation signal was verified, and the broad technology selloff adds risk.

Consensus points to Q3 EPS of about $2.85–$2.89 and revenue of $4.75B, with expected year-over-year growth, but no checked source established positive recent estimate revisions or a revenue upside signal. The latest verified sessions show a declining share price and no qualifying high close location or 1.5x volume confirmation, so the required pre-event tape setup is absent.

EOG has a favorable energy-sector backdrop and a recent Oct. 30 gain on above-average volume, but the official investor-relations schedule places the report on Nov. 6 rather than the supplied Nov. 5 date; checked sources did not establish positive estimate revisions or revenue upside, and the latest session alone does not confirm the required accumulation threshold.

Lumentum has a credible AI-optics growth narrative and prior guidance above $1.2B quarterly revenue, but checked sources did not establish a positive pre-event EPS revision/ESP or qualifying close/volume pattern; the Oct. 30 session erased much of the recent advance on heavy trading, so the setup does not meet the required tape confirmation.

Simon Property shares rose into the event and finished Oct. 30 near the session high on above-average, though sub-1.5x, volume. Available consensus implies only modest revenue growth, and checked sources did not establish positive revisions; the previous reported quarter missed the cited EPS consensus and estimates differ substantially by EPS/FFO measure.

Devon has a positive one-month EPS revision signal and modest pre-event price strength, with energy-sector tape positive for the week. However, the checked estimate source shows revenue revisions down over three months, while recent volume did not show 1.5x accumulation; the required revenue-upside and volume confirmations are absent.

Estimate history shows a three-month EPS rise and modest revenue estimate growth, and Atlassian previously reported strong cloud and AI engagement; however, the last pre-event session fell 6.07%, closed near its low, and technology-sector weakness plus unverified accumulation leave the required tape setup incomplete.

ED gained 0.78% over Oct. 23-30 and traded near its recent highs, while Con Edison reaffirmed 2026 adjusted EPS guidance in its Q2 release. The checked sources did not establish positive estimate revisions or revenue upside, and the latest session's close location was weak; this is not a qualifying surprise setup.

Microchip has credible EPS and revenue consensus and a four-quarter EPS beat record, but the latest session fell sharply on unusually heavy volume, no positive near-term estimate revisions or revenue upside were verified, and company confirmation of the scheduled date was not located.

Live Nation has a company-confirmed report date, consensus EPS and revenue, and prior management commentary pointing to robust live-event demand; however, the available EPS history is mixed, no positive revisions or revenue upside were verified, and the short-window tape supplies no qualifying volume confirmation.

Estimate trends and prior execution support operating momentum, but the supplied Nov. 5 date conflicts with Arm IR's Nov. 4 webcast notice. The stock fell 9.97% on Oct. 30 on roughly 10.56M shares, closing near its session low; that high-volume selloff and weak immediate tape outweigh the positive estimate trend.

MRNA had a sharp late-October rebound and one recent close in the upper quarter of its session range, but the checked sources did not establish positive EPS revisions, an upside revenue indicator, or a recent >1.5x-volume accumulation session; the setup does not meet required earnings-surprise signals.

BAM has a credible upcoming Q3 calendar listing and published consensus estimates, while recent company results described growth in fee-bearing capital and fee-related earnings. The checked sources also show downward estimate movement and weak post-Q2 drift; recent price/volume and sector tape could not be verified, leaving no qualifying pre-event surprise setup.

Humana confirmed its Nov. 6 release date and consensus sources show a deeply negative Q3 EPS outlook with recent estimate downgrades; revenue is expected to grow year over year, but no positive revenue revision was verified. A recent EPS beat streak does not offset the weak revisions and missing final tape/sector confirmation.

Vistra confirmed its November 6 report date, and its Q2 release reaffirmed 2026 guidance; third-party estimates imply substantial year-over-year growth. But the prior quarter materially missed one published consensus, recent shares fell sharply from October highs, and no positive EPS revision or volume-accumulation signal was verified.